Chemotherapy With or Without Bevacizumab as Treatment after Surgery for Early Non-Small Lung Cancer
The purpose of this study is to determine if adding bevacizumab to chemotherapy improves how well it works when treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from reproducing; Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Using chemotherapy after surgery may kill tumor cells that might still be in the body after surgery that removed the tumor mass. The primary objective is to see if the addition of bevacizumab to chemotherapy improves the overall survival for patients with completely resected stage IB (tumors ≥ 4cm)-IIIA non-small cell lung cancer. The study will enroll 1,500 participants from many cancer centers in the US, Canada, Ireland, and South Africa. In addition to other conditions for enrollment, participants are enrolled within 6 to 12 weeks of the surgery to remove the lung cancer. Eligible patients have not been previously treated with chemotherapy.